This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Salvatore, G. Articles by Pastan, I. Search for Related Content PubMed PubMed Citation Articles by Salvatore, G. Articles by Pastan, I. Related Collections Commentary

Improved Cytotoxic Activity toward Cell Lines and Fresh Leukemia Cells of a Mutant Anti-CD22 Immunotoxin Obtained by Antibody Phage Display

Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892-4264

Recombinant immunotoxins are fusion proteins composed of the Fv domains of antibodies fused to bacterial or plant toxins that are being developed for the targeted therapy of cancer. RFB4 (Fv)-Pseudomonas exotoxin 38 (PE38) is an immunotoxin that targets CD22 expressed on B cells and B-cell malignancies. A disulfide-stabilized form of RFB4 (Fv)-PE38 is being evaluated in a Phase I clinical trial. The aim of the present study was to improve the activity of RFB4 (Fv)-PE38 to more effectively treat patients with leukemias and lymphomas. To increase the affinity of RFB4 (Fv), we used the techniques of phage display and hot spot mutagenesis. We identified mutational hot spot sequences in heavy chain complementary determining region 3 (V_H CDR3) and randomized these in a phage display library. Mutant phages were panned on CD22-positive Daudi cells. A variety of mutant Fvs were obtained, and the corresponding immunotoxins were prepared. Several mutant immunotoxins with increased binding affinity and cytotoxic activity were obtained. The most active immunotoxin contained amino acid residues Thr-His-Trp (THW) in place of Ser-Ser-Tyr (SSY) at positions 100, 100A, and 100B of the Fv and had an affinity improved from 85 nM to 6 nM. The THW mutant had a 5- to 10-fold increase in activity on various CD22-positive cell lines and was up to 50 times more cytotoxic to cells from patients with chronic lymphocytic leukemia and hairy-cell leukemia.

Commentary

Increased Sophistication of Immunotoxins

Arthur E. Frankel
Clin. Cancer Res. 2002 8: 942-944. [Full Text] [PDF]

This article has been cited by other articles:

				K. Matsushita, I. Margulies, M. Onda, S. Nagata, M. Stetler-Stevenson, and R. J. Kreitman Soluble CD22 as a tumor marker for hairy cell leukemia Blood, September 15, 2008; 112(6): 2272 - 2277. [Abstract] [Full Text] [PDF]

				M. Onda, R. Beers, L. Xiang, S. Nagata, Q.-c. Wang, and I. Pastan An immunotoxin with greatly reduced immunogenicity by identification and removal of B cell epitopes PNAS, August 12, 2008; 105(32): 11311 - 11316. [Abstract] [Full Text] [PDF]

				X. Du, R. Beers, D. J. FitzGerald, and I. Pastan Differential Cellular Internalization of Anti-CD19 and -CD22 Immunotoxins Results in Different Cytotoxic Activity Cancer Res., August 1, 2008; 68(15): 6300 - 6305. [Abstract] [Full Text] [PDF]

				R. Hassan, V. C. Broaddus, S. Wilson, D. J. Liewehr, and J. Zhang Anti Mesothelin Immunotoxin SS1P in Combination with Gemcitabine Results in Increased Activity against Mesothelin-Expressing Tumor Xenografts Clin. Cancer Res., December 1, 2007; 13(23): 7166 - 7171. [Abstract] [Full Text] [PDF]

				M. Ho, S. Nagata, and I. Pastan Isolation of anti-CD22 Fv with high affinity by Fv display on human cells PNAS, June 20, 2006; 103(25): 9637 - 9642. [Abstract] [Full Text] [PDF]

				R. J. Kreitman, D. R. Squires, M. Stetler-Stevenson, P. Noel, D. J.P. FitzGerald, W. H. Wilson, and I. Pastan Phase I Trial of Recombinant Immunotoxin RFB4(dsFv)-PE38 (BL22) in Patients With B-Cell Malignancies J. Clin. Oncol., September 20, 2005; 23(27): 6719 - 6729. [Abstract] [Full Text] [PDF]

				S. Nagata, T. Ise, M. Onda, K. Nakamura, M. Ho, A. Raubitschek, and I. H. Pastan Cell membrane-specific epitopes on CD30: Potentially superior targets for immunotherapy PNAS, May 31, 2005; 102(22): 7946 - 7951. [Abstract] [Full Text] [PDF]

				M. Ho, R. Hassan, J. Zhang, Q.-c. Wang, M. Onda, T. Bera, and I. Pastan Humoral Immune Response to Mesothelin in Mesothelioma and Ovarian Cancer Patients Clin. Cancer Res., May 15, 2005; 11(10): 3814 - 3820. [Abstract] [Full Text] [PDF]

				D. A. Vallera, D. A. Todhunter, D. W. Kuroki, Y. Shu, A. Sicheneder, and H. Chen A Bispecific Recombinant Immunotoxin, DT2219, Targeting Human CD19 and CD22 Receptors in a Mouse Xenograft Model of B-Cell Leukemia/Lymphoma Clin. Cancer Res., May 15, 2005; 11(10): 3879 - 3888. [Abstract] [Full Text] [PDF]

				S. Bang, S. Nagata, M. Onda, R. J. Kreitman, and I. Pastan HA22 (R490A) Is a Recombinant Immunotoxin with Increased Antitumor Activity without an Increase in Animal Toxicity Clin. Cancer Res., February 15, 2005; 11(4): 1545 - 1550. [Abstract] [Full Text] [PDF]

				M. Ho, R. J. Kreitman, M. Onda, and I. Pastan In Vitro Antibody Evolution Targeting Germline Hot Spots to Increase Activity of an Anti-CD22 Immunotoxin J. Biol. Chem., January 7, 2005; 280(1): 607 - 617. [Abstract] [Full Text] [PDF]

				Session 9: Cancer Therapy Toxicol Pathol, October 1, 2004; 32(6): 745 - 746. [PDF]

				T. Decker, M. Oelsner, R. J. Kreitman, G. Salvatore, Q.-c. Wang, I. Pastan, C. Peschel, and T. Licht Induction of caspase-dependent programmed cell death in B-cell chronic lymphocytic leukemia by anti-CD22 immunotoxins Blood, April 1, 2004; 103(7): 2718 - 2726. [Abstract] [Full Text] [PDF]

				M. Onda, Q.-c. Wang, H.-f. Guo, N.-K. V. Cheung, and I. Pastan In Vitro and in Vivo Cytotoxic Activities of Recombinant Immunotoxin 8H9(Fv)-PE38 against Breast Cancer, Osteosarcoma, and Neuroblastoma Cancer Res., February 15, 2004; 64(4): 1419 - 1424. [Abstract] [Full Text] [PDF]